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Abstract
Background: Genomic rearrangements involving the ETS family of transcription factors occur in 40–70% of prostate cancer
cases. ERG and ETV1 are the most common ETS members observed in these genetic alterations. The high prevalence of
these rearrangements and their biological significance represents a novel therapeutic target for the treatment of prostate
cancer.
Methods and Findings: We recently reported the development of YK-4-279, a small molecule inhibitor of EWS-FLI1
oncoprotein in Ewing’s Sarcoma. Since ERG and ETV1 belong to the same class of ETS factors as FLI1, we tested the ability of
YK-4-279 to inhibit biological functions of ERG and ETV1 proteins in prostate cancer. YK-4-279 inhibited ERG and ETV1
mediated transcriptional activity in a luciferase assay. YK-4-279 also decreased ERG and ETV1 downstream target mRNA and
protein expression in ETV1-fusion positive LNCaP and ERG fusion positive VCaP cells. YK-4-279 reduced the motility of LNCaP
cells in a scratch assay and the invasive phenotype of both LNCaP and VCaP cells in a HUVEC invasion assay. Fusion-negative
PC3 cells were unresponsive to YK-4-279. SiRNA mediated ERG knockdown in VCaP cells resulted in a loss of drug
responsiveness. Concurrently, transient ERG expression in PC-3 cells resulted in increased invasive potential, which was
reduced by YK-4-279.
Conclusion: These data demonstrate that YK-4-279 inhibits ERG and ETV1 biological activity in fusion-positive prostate
cancer cells leading to decreased motility and invasion. Therefore, YK-4-279 may have an impact on metastasis in prostate
cancer and it may be further evaluated for its clinical applications in prostate cancer in addition to Ewing’s sarcoma.
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Introduction
Prostate cancer is the most common form of cancer and the
second most leading cause of cancer mortality in men.
Chromosomal translocations involving the ETS family of
transcription factors are present in 40–70% of prostate cancers,
including the most clinically aggressive forms [1,2,3,4,5]. These
translocations produce chimeric genes, which fuse the promoter
region of an androgen responsive gene, such as TMPRSS2, to the
coding region of ETS factors, most frequently ETV1 or ERG [6,7].
These rearrangements lead to androgen dependent regulation of
ETS transcription factors and their overexpression. ETS proteins
are proto-oncogenes that have been implicated in pathogenesis
[8]. They control expression of target genes involved in cell
proliferation, apoptosis, invasion and angiogenesis. Over-expres-
sion of ETS factors in prostate cancer cells increase cell invasion
and induces prostatic intraepithelial neoplasia (PIN) in transgenic
mouse models [9]. Depletion of ETS factors in vitro reduces
motility and invasiveness. ERG and ETV1 depletion also result in
reduced tumor growth in vivo [7]. Recent results also indicate that
TMPRSS2-ERG expression is reactivated in castration resistant
prostate cancer [10]. Thus, ETS proteins represent a novel target
for prevention or treatment of metastatic disease.
We recently reported a small molecule inhibitor of the chimeric
protein EWS-FLI1 in Ewing’s sarcoma [11]. YK-4-279 inhibits
EWS-FLI1 activity, induces apoptosis in Ewing’s sarcoma cell lines
and slows down tumor growth in mouse xenograft models. FLI1,
ERG and ETV1 are Class I ETS factors and share greater than
60% identity and 80% homology in their amino acid sequences
[12]. Due to the close homology of FLI1 with ERG and ETV1, we
tested the ability of YK-4-279 to inhibit ETS gene activity in
prostate cell-lines that demonstrate androgen dependent ERG and
ETV1 expression. Our results indicate that YK-4-279 can inhibit
ERG and ETV1 dependent transcriptional activity and conse-
quently leads to reduced cell motility and invasion.
Results and Discussion
VCaP and LNCaP cells are androgen-responsive and
harbor ERG and ETV1 rearrangements
Prostate requires androgens to function properly and androgen
responsiveness can be used as a basis for grouping prostate cancer
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19343cell lines into either of two categories: androgen-sensitive and
androgen-resistant. In the majority of ETS rearrangement cases,
the ETS gene is placed under direct regulation of an androgen-
responsive gene promoter. In these cases, androgen mediates over-
expression of the oncogenic ETS factor. In order to study the
effect of ETS inhibitors in prostate cancer, we selected to work
with VCaP and LNCaP cell-lines. The VCaP cell-line harbors a
TMPRSS2-ERG rearrangement, which occurs via interstitial
deletion of the 3 Mb region between TMPRSS2 and ERG on
chromosome 21 (Fig. 1a) [6]. The LNCaP cell-line contains a
genetic translocation where the entire ETV1 locus is inserted in
the last intron of the prostate-specific MIPOL1 region on
chromosome 14 (Fig. 1a) [7]. The ERG and ETV1 rearrange-
ments are mutually exclusive to VCaP and LNCaP cells
respectively, and are not present in the PC-3 cell line. Thus, the
PC-3 cell-line was selected as a negative control for our studies.
We validated that both VCaP and LNCaP cells are androgen-
sensitive, as demonstrated by an increase in prostate specific
antigen (PSA) expression upon stimulation by the synthetic
androgen analogue R1881 (Fig. 1b). VCaP and LNCaP cells
express ERG and ETV1 proteins under basal conditions owing to
the presence of ETS rearrangements in these cells. Androgen
treatment of these cell-lines, but not PC-3, results in increased
ERG and ETV1 mRNA and protein (Fig. 1c and d). These results
establish that both VCaP and LNCaP cells are androgen
responsive while PC-3 cells are not. Androgen responsiveness of
VCaP and LNCaP cells translates to enhanced ETV1 and ERG
expression due to prostate cancer specific chromosomal rear-
rangements.
YK-4-279 inhibits ERG and ETV1 transcriptional activity
YK-4-279 targets the EWS-FLI1 oncoprotein in Ewing’s
Sarcoma [11]. However, the site of interaction with EWS-FLI1
is unknown. Considering the close homology between FLI1, ERG
and ETV1, we investigated the effects of YK-4-279 on ERG and
ETV1 function. We first evaluated the expression of FLI1 in
prostate cells. The human acute lymphoblastic leukemia cell line
MOLT4 was used as a control for FLI1 expression, under basal
conditions. None of the prostate cells used in this study express
FLI1 (Fig. 1d). Hence, the effects of YK-4-279 on prostate cells
would not occur as a result of targeting FLI1. Next, we validated
the direct interaction between YK-4-279 and recombinant ERG
and ETV1 proteins using surface plasmon resonance (SPR). YK-4-
279 bound to ERG with an affinity (KD) of 11.7 mM and bound to
ETV1 with an affinity of 17.4 mM (Fig. 2a, S1). We evaluated YK-
4-279 for effects upon ERG transcriptional activity using a
transiently transfected 207 bp fragment of the Id2 gene promoter
that directs expression of luciferase protein. This minimal Id2
promoter region contains two ETS sites and has been previously
shown to bind ERG [13]. Co-transfection of ERG and Id2
reporter resulted in an increase in luciferase activity. Promoter
activity was reduced by simultaneous treatment of the cells with
YK-4-279, without any appreciable decrease in ERG protein
levels (Fig. 2b).
Next, we evaluated the effects of YK-4-279 on expression of
endogenous ERG and ETV1 target genes in VCaP and LNCaP
cell-lines. We focused on several members of the plasminogen
activator pathway such as PLAU, PLAT, MMP13 and ADAM19.
These genes mediate an invasive phenotype in several cancers and
have been reported as direct targets of ETS transcription factors
[9,14,15]. Exposure of VCaP cells to 10 mM YK-4-279 for
48 hours resulted in significantly reduced mRNA and protein
levels of several ERG target genes, such as PLAU, PLAT and
ADAM29. The level of down-regulation was comparable to that
obtained by siRNA mediated ERG knock-down in VCaP cells
(Fig. 2c). Similarly, YK-4-279 resulted in down-regulation of
ETV1 target gene MMP-13 in LNCaP cells (Fig. 2d). It should be
noted that this inhibition of ERG and ETV1 protein activity was
obtained without any significant decrease in ERG or ETV1
protein levels. These results suggest that YK-4-279 is able to
inhibit ERG and ETV1 transcriptional activity in prostate cancer
cells, leading to decreased expression of genes that are involved in
breakdown of extracellular matrix and metastasis.
YK-4-279 inhibits ETS mediated prostate cancer cell
invasion
Previous studies have suggested that ETS gene rearrangements
mediate invasion in prostate cancer [7,9]. To address the question
whether YK-4-279 is able to inhibit ERG and ETV1 mediated
invasion, we utilized an impedance based endothelial cell invasion
assay [16]. This technique involves challenging a confluent
monolayer of human umbilical vein endothelial cells (HUVECs)
with a second layer of metastatic cells that attach to, and invade
the HUVEC monolayer. The retraction of endothelial cell
junctions and invasion of prostate cancer cells can be monitored
in real-time by measuring the decrease in electrical resistance on
gold electrodes [17].
A cytotoxicity assay was performed to determine the maximum
tolerable dose of YK-4-279 in different prostate cancer cell lines.
YK-4-279 did not show any significant reduction in cell growth at
1 mM for LNCaP cells and 10 mM for VCaP and PC3 cells after 2
days of treatment (data not shown). These doses were selected for
further functional assays in order to ensure that inhibitory effects
of YK-4-279 on invasion and motility, are not as a result of cell
death. When HUVEC cells were challenged with LNCaP and
VCaP cells, it led to a steep decrease in electric-resistance
indicative of cell invasion. Treating these cells with YK-4-279
resulted in significantly decreased invasion of HUVEC cells by
LNCaP and VCaP cells. The compound alone had no effect on
the HUVEC cell monolayer. YK-4-279 did not inhibit invasion by
ETS-fusion negative PC-3 cells. (Fig. 3a and b). To ensure that the
effects observed were due to inhibition of ETS proteins, we
reduced ERG protein expression in VCaP cells using siRNA. This
resulted in abrogation of YK-4-279 mediated inhibition of
invasion (Fig. 3c). Next, we transiently expressed ERG in PC-3
cells and assayed these cells in the endothelial cell invasion assay.
ERG expression alone in PC-3 cells imparted upon these cells a
more invasive phenotype. Treatment with YK-4-279 significantly
inhibited the ERG mediated increase in invasion (Fig. 3d).
Together, these results suggest that YK-4-279 is able to inhibit
ETS-mediated invasion of prostate cancer cells, both in cells with
endogenous and exogenous high expression of ETS proteins.
YK-4-279 inhibits ETV1 mediated motility in LNCaP Cells
Next, we tested the effects of YK-4-279 on inhibition of motility
of LNCaP cells in a scratch assay. All experiments in previous
figures were performed with low passage LNCaP cells (p,30).
However, low-passage LNCaP cells were not amenable to this
technique as they loosely attach to the cell-culture dish surface.
Similarly, VCaP cells grow in clumps and do not form a confluent
monolayer. Therefore, we performed scratch assays using high
passage LNCaP cells (p.60). High-passage LNCaP cells grow at a
much faster rate and are able to form a confluent monolayer [18].
They also express high basal levels of ETV1 (Fig. 4a) [19]. Prior to
performing the scratch assay, YK-4-279 was tested for its cytostatic
nature and was found to have no effects on cell-proliferation at
concentrations used for the scratch assay (Fig. S2). YK-4-279
treatment of LNCaP cells resulted in a significant decrease in cell
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PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19343Figure 1. LNCaP and VCaP cells are androgen responsive and harbor ERG and ETV1 rearrangements. a) Prostate cells were analyzed for
ETS rearrangement status by performing PCR using rearrangement specific primer. VCaP cells harbor the TMPRSS-ERG rearrangement whereas LNCaP
cells contain rearranged ETV1. VCaP and LNCaP cells express ERG and ETV1 protein respectively, under basal conditions. PC-3 cells do not contain
either rearrangement and do not express ERG or ETV1. b) VCaP and LNCaP cells express PSA in response to R1881 treatment. PC-3 cells are not
androgen responsive. Cells were treated with 10 nM R1881 for 48 hours and PSA expression was analyzed by real-time qPCR. Results were
normalized to actin. * ; p,0.0001, n.s.; not-significant. c) R1881 stimulation results in increased ERG and ETV1 mRNA in VCaP and LNCaP cells
respectively, but not in PC3 cells. RNA was isolated from androgen stimulated cells and used to perform real-time qPCR. Data was normalized to the
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motility of the negative control cell-line, PC-3 (Fig. 4b). The
scratch assay was also performed with pre-treatment of LNCaP
cells with 10 mg/ml mitomycin C for 2 hours prior to scratching
the surface. YK-4-279 was able to inhibit LNCaP cell motility in
mitomycin treated conditions as well (Fig. S3) These findings
suggest that the effects of YK-4-279 on LNCaP cells in scratch
assay is not due to cytotoxicity, but solely due to inhibition of cell
motility.
The EWS-FLI1 oncoprotein is dependent upon binding to
RNA Helicase A (RHA) for its oncogenic function [20]. YK-4-279
induces apoptosis in Ewing’s sarcoma cells by blocking the
interaction between EWS-FLI1 and RHA. As a possible
mechanism for the activity of YK-4-279 in prostate cancer, we
tested whether the interaction between an ETS family member
and RHA is present in prostate cells as well. While ERG does
interact with RHA in prostate cancer cells, YK-4-279 is unable to
block this interaction (Fig. S4). We also tested whether YK-4-279
is able to block ERG or ETV1 binding to ETS sites on the DNA
by using surface plasmon resonance. YK-4-279 did not inhibit
ERG or ETV1 DNA binding (Fig. S5a). Furthermore, chromatin
immunoprecipitation was performed to evaluate ERG binding to
PLAU promoter in the presence of YK-4-279. Results confirmed
Biacore findings that YK-4-279 does not interfere with ERG DNA
binding (Fig S5b). It should be noted that Ewing’s cells express a
truncated FLI1 protein containing only exons 6–9 of FLI1. ETS
translocations in prostate cancer, on the other hand, result in the
expression of an almost full-length ETS family member.
Figure 2. YK-4-279 inhibits ERG and ETV1 transcriptional activity. a) Binding kinetics of YK-4-279 to ERG and ETV1 was determined by
surface plasmon resonance. YK-4-279 bound to ERG and ETV1 with a KD of 11.7 mM and 17.9 mM respectively. SPR sensorgrams are provided in
supplementary figures (Fig. S1). b) A luciferase assay was performed in Cos-7 cells co-transfected with ERG and an Id-2 reporter luciferase construct.
Id-2 promoter activity was decreased upon YK-4-279 treatment without affecting ERG protein levels. * ; p,0.001. c) VCaP cells were treated with
50 nM siERG or 10 mM YK-4-279 for 48 hours and mRNA and protein expression levels of ERG targets were evaluated. YK-4-279 treatment resulted in
decreased expression of PLAU, ADAM19 and PLAT mRNA. PLAU and PLAT protein levels were decreased as well. Results were comparable to those
obtained by siRNA mediated ERG knockdown. d) LNCaP cells were treated with 1 mM YK-4-279 and ETV1 target gene levels were evaluated. YK-4-279
treatment resulted in decreased gene expression of MMP13 without significant reduction in ETV1 levels. * ; p,0.01.
doi:10.1371/journal.pone.0019343.g002
level of gene expression in the absence of androgen. d) ERG and ETV1 proteins are expressed in VCaP and LNCaP cells respectively, but not in PC-3
cells. Androgen stimulation resulted in increased ERG and ETV1 protein in VCaP and LNCaP cells. Prostate cells did not express FLI1 protein under
basal or androgen stimulated conditions. MOLT4 was used as a positive control cell-line for FLI1 expression.
doi:10.1371/journal.pone.0019343.g001
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ERG function in prostate cancer cells by preventing protein-
protein interactions that are different than EWS-FLI1 partners in
Ewing’s Sarcoma. Hence, further investigation is required to
determine the exact molecular mechanism of YK-4-279 mediated
inhibition of ERG and ETV1 function in prostate cancer cells.
The outcome of ETV1 inhibition appears to be more potent
than ERG inhibition, in terms of cell-motility and invasion.
However, this phenomenon cannot be conclusively attributed to
better ETV1 inhibition, as a fair comparison of the data is
complicated by the fact that ERG and ETV1 are expressed in
different cell-lines. Thus, the quality of response may also be a
factor of differences between LNCaP and VCaP cells. Further
experiments, such as measuring the magnitude of ERG and ETV1
response in the same cell-line, would be required to conclusively
address this point.
Recent reports have suggested that ETS knock-down in prostate
cancer cells may result in decreased proliferation in cells expressing
these oncoproteins [21,22]. Although the experiments in this
manuscript were performed at doses and time intervals that were
not toxic to the cells, there does appear to be a direct correlation
between the expression of ETS proteins and YK-4-279 cytotoxicity.
ETS-rearrangement negativePC-3 and DU-145cellsshow minimal
response to YK-4-279 treatment (IC50.100 mM).On the contrary,
YK-4-279 is more toxic to both VCaP (IC50=9.55 mM after 72 h)
and LNCaP cells (2.75 mM after 72 h). Hence, YK-4-279 can also
be evaluated for its cytotoxic potentials in ETS-rearrangement
positive prostate cancer cells in future studies.
Figure 3. YK-4-279 inhibits ETS mediated prostate cancer cell invasion. a) HUVEC cells forming a confluent monolayer were challenged with
LNCaP, VCaP and PC-3 cells with or without YK-4-279. YK-4-279 inhibited VCaP (10 mM) and LNCaP (1 mM) cell invasion of HUVECs, whereas PC-3 cells
were not affected. Prostate cells were pre-treated with YK-4-279. Experiments were performed in duplicates and resistance was normalized to the
time of addition of invading cells. b) Invasion was quantified at 10 hours post-addition of prostate cancer cells. Results are expressed relative to non-
treated conditions. * ; p,0.01. c) ERG expression was reduced in VCaP cells using a C-terminal siRNA probe. ERG knockdown in VCaP cells resulted in
a loss of YK-4-279 mediated inhibition of invasion. VCaP cells were pre-treated with 10 mM YK-4-279 for 2 days prior to challenging the HUVEC
monolayer. * ; p,0.01, d) Transient ERG expression in PC-3 cells imparted upon the cells a more invasive phenotype. Subsequently, YK-4-279
treatment resulted in decreased invasion. PC-3 cells were treated with YK-4-279 for 24 h prior to challenging the HUVEC monolayer.
doi:10.1371/journal.pone.0019343.g003
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protein in prostate cancer cells has been directly implicated to
increased invasion and metastasis. Furthermore, multiple studies
have correlated the increased expression of these proteins with
poor prognosis, higher Gleason scores and a lower incidence of
recurrence free survival. Currently, androgen dependent signaling
pathways in prostate cancer are targeted via castration and
androgen receptor antagonists. The effects of these treatments can
be in part attributed to the downregulation of rearranged ETS
factors. Thus, the successful development of small molecule
inhibitors of ERG and ETV1, such as YK-4-279, will represent
a novel line of therapeutics aimed at preventing or treating
metastatic disease, while saving patients the long-term effects of
therapies targeting the androgen pathway.
Materials and Methods
Cell Culture
VCaP, LNCaP, PC-3 and DU-145 cells were obtained from
ATCC (American Type Culture Collection, Manassas, VA).
HUVECs were obtained from Lonza Biosciences (Allendale, NJ).
VCaP cells were maintained in DMEM media supplemented with
10% Fetal Bovine Serum. LNCaP, PC-3 and DU-145 cells were
maintained in RPMI media supplemented with 10% FBS and 1%
HEPES. HUVEC cells were cultured in EBM-2 media (Lonza)
supplemented with EGM-2 bullet kit (Lonza) containing growth
factors, antibiotics and 5% FBS.
Western-Blots
Protein lysates were prepared and western-blots performed as
previously described [23]. ERG (sc-354), ETV1 (sc-1953) FLI1 (sc-
356), PLAT (sc-5241) and actin (sc-1615) antibodies were
purchased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Anti-PLAU antibody was purchased from Calbiochem
(Gibbstown, NJ).
mRNA isolation and qPCR
mRNA was isolated using TRIzol (Invitrogen, Carlsbad, CA)
and cDNA was prepared using transcriptor first-strand cDNA
synthesis kit (Roche, San Francisco, CA) according to manufac-
turer’s protocol. qRT-PCR was carried out using SYBR green
(Roche) on a Mastercycler realplex
4 instrument (Eppendorf, New
Figure 4. YK-4-279 inhibits ETV1 mediated motility in LNCaP cells. a) High-passage LNCaP cells were analyzed for ETV1 expression levels. HP-
LNCaP cells constitutively express higher amounts of ETV1, as compared to PC-3 cells. b) YK-4-279 inhibited motility in a scratch assay in high-passage
LNCaP cells, whereas PC-3 cells were unresponsive. Cell motility was quantified by measuring the distance between the migrating cell boundaries.
Motility was expressed relative to vehicle treated conditions. * ; p,0.0001.
doi:10.1371/journal.pone.0019343.g004
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are listed in Supplementary Table S1.
Rearrangement status
Genomic DNA was isolated from PC-3, LNCaP and VCaP cells
using Wizard genomic DNA extraction kit (Promega, Madison,
WI) according to manufacturer’s protocols. PCR was carried out
using primers flanking rearrangement sites. Primer sequences can
be found in Supplementary Table S1.
Binding Kinetics
Steady state binding affinities were measured on a Biacore T100
instrument. Recombinant ERG and ETV1 (Origene, Rockville,
MD) proteins were immobilized on CM5 chips by amine coupling
and 6 different concentrations of YK-4-279 were injected over the
surface in duplicates. SPR sensorgrams and KD values were
obtained using Biacore T100 software.
Luciferase Assay
Cos-7 cells were co-transfected with a lentiviral plasmid
expressing the most-commonly found truncated ERG mRNA,
and a vector containing Id2 gene promoter driving expression of a
luciferase gene. Transfection was carried out using Fugene 6
(Roche) according to the manufacturer’s protocols. A lentiviral
vector expressing LacZ was used as a negative control. Cells were
allowed to express ERG for 48 hours and subsequently they were
treated with 10 mM YK-4-279. Luciferase activity was measured
after 24 h using a dual luciferase assay kit according the
manufacturer’s protocol (Promega, Madison, WI). Results were
normalized to total protein concentration. Statistical analysis was
performed using GraphPad Prism 4.0.
Androgen and YK-4-279 treatment
For androgen treatment, cells were seeded in phenol-red free
media containing 10% charcoal-stripped FBS and allowed to
attach to the cell-culture dish overnight. Subsequently, cells
were serum starved for 48 hours in phenol-red free media and
then stimulated with 10 nM R1881 (Sigma, St-Louis, MO) for
2d a y s .
YK-4-279 was dissolved in DMSO to prepare 10 mM stock.
Logarithmically growing cells were treated with 1 mMo r1 0mM
YK-4-279 for 48 hours prior to assessing for gene expression.
siRNA ERG knockdown
Transient ERG knockdown was performed using a custom
siRNA (59-CGACATCCTTCTCTCACAT-39) directed against
the C-terminus of ERG (Dharmacon, Lafayette, CO) [21]. 50 nM
siRNA was transfected using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocols. Cells were analyzed for
ERG knockdown 5 days after transfection with siRNA.
Transient ERG Expression
PC-3 cells were transfected with a pLenti6/V5-DEST plasmid
(Invitrogen) expressing the most-commonly found truncated ERG
isoform. Transfection was carried out using Fugene 6 reagent
(Roche) according to the manufacturer’s protocols for 48 hours.
HUVEC Invasion
The anti-invasive potential of YK-4-279 was measured by using
the technique of electric cell impedance sensing (ECIS) on ECIS Z
instrument (Applied Biophysics, Troy, NY) and xCELLigence
system (Roche). Briefly, 250,000 HUVEC cells were seeded in
8W10E+ arrays with electrode circuitry at well bottom to measure
electrical resistance. Following formation of a confluent HUVEC
monolayer (app. 21–24 hrs), the invading prostate cancer cells
were added at a density of 100,000 cells per well in DMEM or
RPMI media containing the indicated drug concentrations.
Tumor cells were pre-treated for 24–48 hours with YK-4-279
before addition. This time point of tumor cell addition was
accepted as 0 hr of treatment and invasion was monitored during
the following 12 hours by measuring changes in resistance at the
cell-electrode interphase. The experiments were performed in
duplicates. Resistance was normalized to time of addition of
invading cells.
Scratch Assay
Cells were plated and allowed to form a confluent mono-layer.
The cell-surface was scratched using a p-200 pipette tip. Cells were
allowed to fill the scratched area and monitored over the course of
72 hours. Images were taken using a Nikon Eclipse Ti microscope
(Nikon, Melville, NY). Cell motility was quantified by measuring
the distance between the migrating cell boundaries.
Chromatin Immunoprecipitation (ChIP)
PC-3 cells were transfected with a pLenti6/V5-DEST plasmid
(Invitrogen) expressing the most commonly found truncated ERG
isoform. Transfection was carried out using Fugene 6 reagen-
t(Roche) according to the manufacturer’s protocols for 24 hours.
Cells were then treated for 6 hrs with 10 mM vehicle or YK-4-279.
ChIP was carried out using EZMagna Protein A ChIP Kit from
Millipore according to the manufacturer’s instructions. Immuno-
precipitation was carried out using 2 mg of ERG antibody (SC-
354x, Santa Cruz Biotechnology), 2 mg Normal Rabbit IgG
(Sigma Aldrich) and 1 mg of Pol II (Millipore). PCR was carried
out using primers previously published for positive ERG binding
at the PLAU promoter in prostate cells [9]. A PCR profile of
94uC–5 min : 1 cycle, 94uC–30 sec, 55uC–30 sec, 72uC–1 min :
35 cycles, 72uC–5 min: 1 cycle was used on an Eppendorf
Realplex4 thermocycler.
Statistical Analysis
Groups were compared using a two-tailed Student’s t-test (Prism
4, GraphPad Software, La Jolla, CA) and p,0.05 was considered
significant.
Supporting Information
Figure S1 SPR sensorgrams for YK-4-279 binding to
ERG and ETV1. Steady state binding affinities were measured
by injecting 6 different concentrations of YK-4-279 over
recombinant ERG and ETV1 proteins immobilized on the surface
of CM5 chips in a Biacore T100 instrument. SPR sensorgrams
were obtained using Biacore T100 software.
(TIF)
Figure S2 YK-4-279 is not a cytostatic agent. VCaP
(10,000 cells/well), LNCaP-high passage (10,000 cells/well),
LNCaP-low passage (10,000 cells/well) and PC-3 (5,000 cells/
well) cells were seeded overnight in xCELLigence E-16 plates and
allowed to adhere to the well-bottom. The xCELLigence E-16
plates well-bottom is covered with miniature gold-electrodes which
measure changes in electrical resistance on the surface of the
electrodes. Changes in electrical resistance are represented as a
dimensionless parameter termed cell-index, and is directly
proportional to the area of well-bottom covered by electrodes.
Approximately 20 hours after seeding prostate cancer cells, culture
media was replaced with fresh media containing 1 mM (LNCaP,
Small Molecule Inhibitor of ERG and ETV1
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monitored over 72 hours.
(TIF)
Figure S3 YK-4-279 inhibits LNCaP cell motility. Cells
were plated and allowed to form a confluent mono-layer. Cells
were treated with 10 mg/ml mitomycin-C for 2 hours prior to
scratch assay, as described previously [24,25]. After mitomycin-C
treatment, fresh media was added and the cell-surface was
scratched using a p-200 pipette tip. Cells were allowed to fill the
scratched area and monitored over the course of 60 hours. Cell
motility was quantified by measuring the area of scratch not
covered with migrating cells.. Motility was expressed relative to
vehicle treated conditions. * ; p,0.0001
(TIF)
Figure S4 ERG interacts with RHA in VCaP cells. Yk-4-
279 does not block the interaction between ERG and RHA.
9610
7 VCaP cells were seeded in 15 cm dishes and allowed to
attach and spread for 48 hours. Cells were treated with 10 mM
YK-4-279 for 24 h. Immunoprecipitation was performed as
previously described [11].
(TIF)
Figure S5 YK-4-279 does not inhibit ERG or ETV1
binding to DNA. a) Recombinant ERG or ETV1 proteins were
immobilized on the surface of a Biacore CM5 chip by amine
coupling. Wild-type double-stranded oligonucleotides (ATGTA-
GACCGGAAGTAACTA) containing the consensus Ets binding
site ‘‘GGAA’’ were injected in 5 mM triplicates over the surface of
the chip in presence or absence of 50 mM YK-4-279. Binding of
DNA to recombinant ERG or ETV1 was measured using Biacore
T100 software. b) ChIP assay was performed by transfecting PC-3
cells with a lentiviral vector expressing ERG. Cells were treated for
6 hrs with 10 mM vehicle or YK-4-279. YK-4-279 did not inhibit
binding of ERG to PLAU promoter.
(TIF)
Table S1 Primers List
(DOCX)
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